Literature DB >> 11903959

Copper, ceruloplasmin and superoxide dismutase (SOD1) in patients with Down's syndrome.

G Tórsdóttir1, J Kristinsson, S Hreidarsson, J Snaedal, T Jóhannesson.   

Abstract

The aim of this study was primarily to investigate whether similar signs of copper dyshomeostasis occur in dementia with age in Down's syndrome as previously found in Alzheimer's disease. Copper was accordingly determined in plasma, ceruloplasmin concentration in serum, ceruloplasmin oxidative activity and ceruloplasmin specific oxidative activity (activity related to mass) in serum, and superoxide dismutase (SOD1) in erythrocytes in 35 (27 males, 8 females) 18-53 years old (average 37 years) patients with Down's syndrome (Down's patients) and their age- and gender-matched controls. SOD1 activity was on an average almost 50% higher in the patients than in their controls but the evidence of a causal relationship between increased SOD1 activity and Down's syndrome appears at best equivocal. Copper and ceruloplasmin levels and ceruloplasmin activities were similar in the patients and their controls. Ceruloplasmin and copper levels increased significantly with age in the patients but not in the controls. Ceruloplasmin activities or SOD1 activity did not change significantly with age, neither in the patients nor in the controls as whole groups. When SOD1 activity and ceruloplasmin activities of the oldest in the patients group (40 years or older) were compared with those of the younger patients, respectively, SOD1 activity and specific oxidative activity, but not ceruloplasmin oxidative activity were found to decrease significantly with age. The results thus suggest that development of dementia in Down's patients with age is paralleled with decrease in SOD1 activity and specific oxidative activity but not with decrease in ceruloplasmin oxidative activity itself as was also found in Alzheimer's patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11903959     DOI: 10.1034/j.1600-0773.2001.d01-168.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  8 in total

1.  Does ceruloplasmin differential express in the brain of Ts65Dn: a mouse mode of Down syndrome?

Authors:  Bin Yu; Jing Kong; Baoling Xing; Ziqiang Zhu; Bin Zhang; Qiu-Wei Wang; Shi-He Shao
Journal:  Neurol Sci       Date:  2013-11-17       Impact factor: 3.307

2.  Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.

Authors:  H Kessler; F-G Pajonk; P Meisser; T Schneider-Axmann; K-H Hoffmann; T Supprian; W Herrmann; R Obeid; G Multhaup; P Falkai; T A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

3.  Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.

Authors:  Thomas A Bayer; Stephanie Schäfer; Andreas Simons; André Kemmling; Thomas Kamer; Ralf Tepest; Anne Eckert; Katrin Schüssel; Oliver Eikenberg; Christine Sturchler-Pierrat; Dorothee Abramowski; Matthias Staufenbiel; Gerd Multhaup
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

Review 4.  Trisomy 21 and the brain.

Authors:  Robert E Mrak; W Sue T Griffin
Journal:  J Neuropathol Exp Neurol       Date:  2004-07       Impact factor: 3.685

5.  Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies.

Authors:  Jakob Kristinsson; Jón Snaedal; Gudlaug Tórsdóttir; Torkell Jóhannesson
Journal:  Neuropsychiatr Dis Treat       Date:  2012-11-02       Impact factor: 2.570

6.  2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome.

Authors:  Wendy E Heywood; Tracey E Madgett; Darrell Wang; Amanda Wallington; Julie Hogg; Kevin Mills; Neil D Avent
Journal:  Proteome Sci       Date:  2011-09-19       Impact factor: 2.480

Review 7.  Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium.

Authors:  Amene Saghazadeh; Maryam Mahmoudi; Atefeh Dehghani Ashkezari; Nooshin Oliaie Rezaie; Nima Rezaei
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

8.  Redox processes in neurodegenerative disease involving reactive oxygen species.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.